About this Journal Submit a Manuscript Table of Contents
Case Reports in Psychiatry
Volume 2012 (2012), Article ID 749796, 3 pages
http://dx.doi.org/10.1155/2012/749796
Case Report

Memantine as an Augmentation Therapy for Anxiety Disorders

Department of Psychiatry, SUNY Upstate Medical University, 750 E. Adams Street, Syracuse, NY 13210, USA

Received 23 August 2011; Accepted 9 October 2011

Academic Editors: I. G. Anghelescu, D. E. Dietrich, Y. Kaneda, J. Nakamura, and J. Saiz-Ruiz

Copyright © 2012 Thomas L. Schwartz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. E. Narrow, D. S. Rae, L. N. Robins, and D. A. Regier, “Revised prevalence estimates of mental disorders in the United States: using a clinical significance criterion to reconcile 2 surveys' estimates,” Archives of General Psychiatry, vol. 59, no. 2, pp. 115–123, 2002. View at Scopus
  2. J. C. Ballenger, “Current treatments of the anxiety disorders in adults,” Biological Psychiatry, vol. 46, no. 11, pp. 1579–1594, 1999. View at Publisher · View at Google Scholar · View at Scopus
  3. T. L. Schwartz, N. Azhar, J. Husain et al., “An open-label study of tiagabine as augmentation therapy for anxiety,” Annals of Clinical Psychiatry, vol. 17, no. 3, pp. 167–172, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. B. M. Cortese and K. L. Phan, “The role of glutamate in anxiety and related disorders,” CNS Spectrums, vol. 10, no. 10, pp. 820–830, 2005. View at Scopus
  5. C. J. Swanson, M. Bures, M. P. Johnson, A. M. Linden, J. A. Monn, and D. D. Schoepp, “Metabotropic glutamate receptors as novel targets for anxiety and stress disorders,” Nature Reviews Drug Discovery, vol. 4, no. 2, pp. 131–144, 2005. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  6. N. Bassil and G. T. Grossberg, “Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease,” CNS Drugs, vol. 23, no. 4, pp. 293–307, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. R. Minkeviciene, P. Banerjee, and H. Tanila, “Cognition-enhancing and anxiolytic effects of memantine,” Neuropharmacology, vol. 54, no. 7, pp. 1079–1085, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. E. Aboujaoude, J. J. Barry, and N. Gamel, “Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial,” Journal of Clinical Psychopharmacology, vol. 29, no. 1, pp. 51–55, 2009. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. M. A. Battista, R. Hierholzer, H. R. Khouzam, A. Barlow, and S. O'Toole, “Pilot trial of memantine in the treatment of posttraumatic stress disorder,” Psychiatry, vol. 70, no. 2, pp. 167–174, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. S. J. Thomas and G. T. Grossberg, “Memantine: a review of studies into its safety and efficacy in treating Alzheimer's disease and other dementias,” Clinical Interventions in Aging, vol. 4, pp. 367–377, 2009. View at Scopus